NCT02748135View on ClinicalTrials.gov

A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

October 6, 2020

Study Completion Date

October 6, 2020

Conditions
Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)
Interventions
DRUG

TB-403 20mg/kg

bi-weekly intravenous doses of TB-403 20mg/kg

DRUG

TB-403 50mg/kg

bi-weekly intravenous doses of TB-403 50mg/kg

DRUG

TB-403 100mg/kg

bi-weekly intravenous doses of TB-403 100mg/kg

DRUG

TB-403 175mg/kg

bi-weekly intravenous doses of TB-403 175mg/kg

Trial Locations (10)

29425

Charleston

49503

Grand Rapids

63104

St Louis

72202

Little Rock

75235

Dallas

78723

Austin

94609

Oakland

06106

Hartford

02115

Boston

07601

Hackensack

Sponsors

Lead Sponsor

Oncurious NV
All Listed Sponsors
collaborator

Beat Childhood Cancer

UNKNOWN

lead

Oncurious NV

INDUSTRY